Mesoblast (MESO) EBIT (2015 - 2023)

Mesoblast's EBIT history runs 9 years deep, the most recent figure standing at -$59.7 million for Q2 2023.

• In Q2 2023, EBIT rose 14.03% year-over-year to -$59.7 million; the TTM figure through Jun 2023 stood at -$1.3 billion (up 37.35% YoY), while the FY2025 annual figure was -$62.0 million, up 4.09% from the prior year.
• EBIT came in at -$59.7 million for Q2 2023 at Mesoblast, up from -$114.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $7.0 billion in Q2 2021 to a low of -$1.6 billion in Q1 2021.
• A 5-year average of $73.0 million and a median of -$201.6 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT soared 19799.2% in 2020 and tumbled 11886.21% in 2021, its largest moves.
• Mesoblast's EBIT stood at -$734.9 million in 2019, then surged by 101.36% to $10.0 million in 2020, then sank by 9855.67% to -$978.4 million in 2021, then climbed by 15.17% to -$830.0 million in 2022, then soared by 92.81% to -$59.7 million in 2023.
• According to Business Quant data, EBIT over the past three periods registered -$59.7 million, -$114.4 million, and -$830.0 million for Q2 2023, Q1 2023, and Q4 2022 respectively.

Peer Comparison